EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immune responses to COVID ‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK ( MUK) nine OPTIMUM trial

Sian E Faustini, Andrew Hall, Sarah Brown iD, Sadie Roberts, Harriet Hill, Zania Stamataki, (PITCH) consortium, Matthew W Jenner, Roger G Owen, Guy Pratt iD, Gordon Cook iD, Alex Richter und 3 weitere

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18714 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Sian E Faustini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: COVID-19, Multiple Myeloma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Research UK, MRF_, Myeloma UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) and anti‐MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID‐19) and other infections. We investigated anti‐severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) antibodies longitudinally in ultra‐high‐risk patients with MM receiving risk‐adapted, intensive anti‐CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross‐reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID‐19, even with intensive anti‐CD38 therapy for high‐risk MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Multiple MyelomaHumansSARS-CoV-2VaccinationImmunityUnited KingdomAntibodies, Viral

Stichwörter der Autor:innen

anti-CD38antibodieshigh-dose therapymultiple myelomasevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Protective Immunity from T cells to COVID-19 in Health workers, Oxford, UK.
  • Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • The Leeds Teaching Hospitals NHS Trust, Leeds, UK.

ORCID-Profile: Sarah Brown, Guy Pratt, Gordon Cook, Martin F Kaiser, Jennifer L J Heaney

Förderung

  • Cancer Research UK
  • MRF_
  • Myeloma UK
  • University of Leeds

Zitieren

APA

Faustini, S. E., Hall, A., Brown, S., Roberts, S., Hill, H., Stamataki, Z., (PITCH) consortium, Jenner, M. W., Owen, R. G., Pratt, G., Cook, G., Richter, A., Drayson, M. T., Kaiser, M. F., & Heaney, J. L. J. (2023). Immune responses to COVID ‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK ( MUK) nine OPTIMUM trial. British Journal of Haematology. https://doi.org/10.1111/bjh.18714

Vancouver

Faustini SE, Hall A, Brown S, Roberts S, Hill H, Stamataki Z, et al. Immune responses to COVID ‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK ( MUK) nine OPTIMUM trial. British Journal of Haematology. 2023. doi:10.1111/bjh.18714

BibTeX
@article{Faustini2023,
  author = {Faustini, Sian E and Hall, Andrew and Brown, Sarah and Roberts, Sadie and Hill, Harriet and Stamataki, Zania and (PITCH) consortium, (PITCH) consortium and Jenner, Matthew W and Owen, Roger G and Pratt, Guy and Cook, Gordon and Richter, Alex and Drayson, Mark T and Kaiser, Martin F and Heaney, Jennifer L J},
  title = {Immune responses to COVID ‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK ( MUK) nine OPTIMUM trial},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18714}
}
Kostenlos starten →